Oligonucleotide

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

Retrieved on: 
Tuesday, September 19, 2023

SEOUL, South Korea, Sept. 19, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.

Key Points: 
  • SEOUL, South Korea, Sept. 19, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.
  • To diversify its operational scope, the new facility will be designed to accommodate different scales of production.
  • With a total investment of $110 million USD, the construction of the new oligonucleotide facility at ST Pharm Banwol Campus planned for completion in 2025 will cover approximately 3,300 squares meters (10,900㎡), standing at a height of 60 meters across 7 floors.
  • Furthermore, ST Pharm is dedicated to reducing its carbon footprint and advancing sustainability.

ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility

Retrieved on: 
Tuesday, September 19, 2023

SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.

Key Points: 
  • SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities.
  • To diversify its operational scope, the new facility will be designed to accommodate different scales of production.
  • With a total investment of $110 million USD, the construction of the new oligonucleotide facility at ST Pharm Banwol Campus planned for completion in 2025 will cover approximately 3,300 squares meters (10,900㎡), standing at a height of 60 meters across 7 floors.
  • Furthermore, ST Pharm is dedicated to reducing its carbon footprint and advancing sustainability.

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

Retrieved on: 
Wednesday, September 6, 2023

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced key highlights from the upcoming presentation of preclinical non-human primate (NHP) data supporting PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology (NMD) being held on September 7-9, 2023 in Ottawa, ON, Canada, and at the 2023 Myotonic Dystrophy Foundation (MDF) Annual Conference being held on September 7-9, 2023 in Washington, D.C.

Key Points: 
  • Additionally, the presentation reported that EDO technology was also shown to improve in vivo nuclear delivery, with 72% of skeletal muscle nuclei in NHPs positive for oligonucleotide following two doses at 30mg/kg.
  • PepGen previously demonstrated that a single dose of 30 mg/kg of PGN-EDODM1 corrected myotonia in the DM1 HSALR mouse model as measured by electrophysiology.
  • Treatment emergent adverse events in this study at these dose levels were transient, mild (grade 1), and reversible and did not require intervention.
  • “We have previously demonstrated the ability of the EDO technology to deliver up to 50 nM of oligonucleotide to biceps in humans following a single dose.

Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer

Retrieved on: 
Wednesday, August 23, 2023

The rates of pancreatic cancer are rising—and are rising faster among younger women, particularly Black women, than among men of the same age.

Key Points: 
  • The rates of pancreatic cancer are rising—and are rising faster among younger women, particularly Black women, than among men of the same age.
  • Addressing this urgent medical need, Oncotelic, through Sapu, is launching a registrational Phase 2b/Phase 3 trial with their TGF-β2 targeting therapy, OT-101 in combination with Standard of Care- (FOLFIRINOX) against pancreatic cancer.
  • Sapu has engaged Cromos Pharma, an international midsized CRO, to assist in the conduct of the trial.
  • Spearheaded by our discovery that suppression of TGFβ2 could more than double survival in pancreatic cancer, we have engineered the trial to deliver a decisive win against pancreatic cancer.

Aurisco's Busy Business Development

Retrieved on: 
Tuesday, August 22, 2023

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Aurisco Pharmaceutical Co., Ltd (Aurisco), a science-based, USFDA inspected CRDMO and cGMP generic API manufacturer, announced today that members of its senior management are scheduled to participate and exhibit, until the end of the year, in the following upcoming conferences and tradeshows:

Key Points: 
  • Aurisco Pharmaceutical will attend and exhibit at a series of conferences and tradeshows in the US and Europe.
  • Join our team at the above events to discuss your challenges in oligonucleotide, peptide and small molecule development.
  • Customers want to expand their collaborations with Aurisco, and we will meet them where the best science and innovation is presented".
  • Rafael Antunes, Vice-President for Business Development in Europe, added further "While we are expanding our pipeline with generic peptides, GalNAc and oligonucleotides, we're also signing CRDMO contracts for new modalities with innovators.

Aurisco's Busy Business Development

Retrieved on: 
Tuesday, August 22, 2023

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Aurisco Pharmaceutical Co., Ltd (Aurisco), a science-based, USFDA inspected CRDMO and cGMP generic API manufacturer, announced today that members of its senior management are scheduled to participate and exhibit, until the end of the year, in the following upcoming conferences and tradeshows:

Key Points: 
  • Aurisco Pharmaceutical will attend and exhibit at a series of conferences and tradeshows in the US and Europe.
  • Join our team at the above events to discuss your challenges in oligonucleotide, peptide and small molecule development.
  • Customers want to expand their collaborations with Aurisco, and we will meet them where the best science and innovation is presented".
  • Rafael Antunes, Vice-President for Business Development in Europe, added further "While we are expanding our pipeline with generic peptides, GalNAc and oligonucleotides, we're also signing CRDMO contracts for new modalities with innovators.

CHOP Researchers Develop Versatile and Low-Cost Technology for Targeted Long-read RNA Sequencing

Retrieved on: 
Tuesday, August 15, 2023

PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ -- In a development that could accelerate the discovery of new diagnostics and treatments, researchers at Children's Hospital of Philadelphia (CHOP) have developed a versatile and low-cost technology for targeted sequencing of full-length RNA molecules. The technology, called TEQUILA-seq, is highly cost-effective compared to commercially available solutions for targeted RNA sequencing and can be adapted for different research and clinical purposes. The details were described in a paper in Nature Communications.

Key Points: 
  • The technology, called TEQUILA-seq, is highly cost-effective compared to commercially available solutions for targeted RNA sequencing and can be adapted for different research and clinical purposes.
  • "Targeted long-read RNA sequencing is a powerful strategy for elucidating the RNA repertoire for any predefined set of genes.
  • They are compatible for both targeted RNA and DNA sequencing, on both long-read and short-read sequencing platforms.
  • "TEQUILA-seq: A versatile and low-cost method for targeted long-read RNA sequencing," Nature Communications, August 8, 2023, DOI: 10.1038/s41467-023-40083-6

Adrestia Acquired by Insmed Incorporated, Bringing its Novel Approach to Tackling Intractable Genetic Diseases to Insmed’s Early-Stage Research Portfolio

Retrieved on: 
Thursday, August 3, 2023

“Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.

Key Points: 
  • “Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.
  • With Insmed, we’re no longer dreaming big, we’re going big.”
    Adrestia’s synthetic rescue platform uses whole genome assays to identify drug targets for genetic diseases in a wide network of functionally connected genes.
  • Sir Steve is University of Cambridge Professor of Biology and Senior Group Leader at the Cancer Research UK Cambridge Institute.
  • J.P. Morgan Securities plc acted as exclusive financial adviser to Adrestia, and Goodwin Procter (UK) LLP acted as Adrestia’s legal counsel.

Xtalks Announces its Life Science Webinar Calendar for August 2023

Retrieved on: 
Wednesday, August 2, 2023

TORONTO, Aug. 2, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, cell and gene therapy, clinical trials, drug discovery & development, laboratory technology, patient recruitment & retention, pharmaceutical and preclinical.
  • TORONTO, Aug. 2, 2023 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!

Bioanalytical Strategies for Gene Therapy: Bioanalysis of Lipid Nanoparticles Encapsulated Antisense Oligonucleotides, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, July 27, 2023

Toronto, July 27, 2023 /PRNewswire-PRWeb/ -- Emerging fields in healthcare, such as gene therapy, hold the key to unlocking new treatments for diseases. To provide greater insights into this burgeoning field, Rafiq Islam, VP of Bioanalysis and Biomarker at Amador Bioscience, and Margaret Costanzo, Associate Principal Scientist of Cell & Gene Therapy at Amador Bioscience, are set to lead a comprehensive and timely webinar on the critical topic of bioanalytical strategies for gene therapy.

Key Points: 
  • Toronto, July 27, 2023 /PRNewswire-PRWeb/ -- Emerging fields in healthcare, such as gene therapy, hold the key to unlocking new treatments for diseases.
  • This webinar, "Bioanalytical Strategies for Gene Therapy: Bioanalysis of Lipid Nanoparticles Encapsulated Antisense Oligonucleotides," aims to shed light on the sophisticated technologies required to deliver gene therapies effectively.
  • These encompass a range of oligonucleotides, with lipid nanoparticles (LPNs) playing a crucial role as carriers targeting specific cells and tissues.
  • This 60-minute session is your chance to stay abreast with the latest strategies and techniques that apply to the bioanalysis of gene therapies.